PHIO PHARMACEUTICALS CORP. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
PHIO PHARMACEUTICALS CORP. (PHIO) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $2.61 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-05
- PHIO PHARMACEUTICALS CORP. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $2.61M, a 18.13% increase from fiscal 2024.
- PHIO PHARMACEUTICALS CORP. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $2.21M, a 13.22% decline from fiscal 2023.
- PHIO PHARMACEUTICALS CORP. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $2.55M, a 11.50% increase from fiscal 2022.
- PHIO PHARMACEUTICALS CORP. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $2.29M, a 47.39% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.61M 10-K · filed 2026-03-05 | |
| 2024-12-31 | $2.21M 10-K · filed 2026-03-05 | -$2.21M 10-K · filed 2025-03-31 |
| 2023-12-31 | $2.55M 10-K · filed 2025-03-31 | |
| 2022-12-31 | $2.29M 10-K · filed 2024-04-01 | |
| 2021-12-31 | $4.34M 10-K · filed 2023-03-22 | -$4.34M 10-K · filed 2022-03-22 |
| 2020-12-31 | $15.33M 10-K · filed 2022-03-22 | -$2.64M 10-K · filed 2021-03-25 |
| 2019-12-31 | -$2.53M 10-K · filed 2021-03-25 | |
| 2018-12-31 | -$2.19M 10-K · filed 2020-03-26 | |
| 2017-12-31 | $3.00M 10-K · filed 2019-03-27 | |
| 2016-12-31 | -$3.63M 10-K · filed 2018-03-26 | |
| 2015-12-31 | -$3.96M 10-K · filed 2017-03-30 | |
| 2014-12-31 | -$3.31M 10-K · filed 2016-03-30 | |
| 2013-12-31 | -$11.13M 10-K · filed 2015-03-30 | $11.13M 10-K · filed 2014-03-28 |
| 2012-12-31 | $2.39M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |